Provider Briefing: Casodex (Bicalutamide) Supply and Availability in 2026

For oncologists, urologists, and other providers managing patients on combined androgen blockade (CAB) therapy, medication availability directly impacts treatment outcomes. This briefing covers the current supply status of Bicalutamide (brand name: Casodex), prescribing considerations, cost and access data, and practical tools to help your patients maintain therapy continuity.

Current Shortage Status

As of Q1 2026, Bicalutamide is not listed on the FDA Drug Shortage Database. Multiple generic manufacturers continue to produce Bicalutamide 50 mg tablets, and the overall supply remains stable at the wholesale and distributor level.

However, providers should be aware that patients are reporting localized stock-outs at retail pharmacies, primarily driven by:

• Just-in-time inventory practices at chain pharmacies
• Isolated backorders from individual generic manufacturers
• Reduced stocking at pharmacies with low Bicalutamide prescription volume
• Increasing off-label prescribing expanding the patient population

These are supply chain distribution issues rather than true manufacturing shortages — an important distinction when counseling patients.

Timeline and Context

Bicalutamide has been available in the U.S. since its FDA approval in 1995. Generic versions have been on the market since 2009, and the medication is now produced by multiple generic manufacturers including Teva, Mylan (Viatris), Sun Pharma, Accord Healthcare, and others.

The drug has not experienced a significant, sustained nationwide shortage in its history. Occasional spot shortages from individual manufacturers have resolved without major disruption to patient access.

Historically, the generic Bicalutamide market has been competitive, keeping prices low and supply generally adequate. The branded product (Casodex by AstraZeneca) is still technically available but is rarely dispensed given the cost differential.

Prescribing Implications

Treatment Continuity

Bicalutamide has a relatively long elimination half-life of approximately 5.8 days (for the active R-enantiomer), which provides some pharmacological buffer if a patient misses 1–2 doses. However, sustained treatment gaps should be avoided, as consistent androgen receptor blockade is important for therapeutic efficacy in combined androgen blockade.

Therapeutic Substitution Considerations

If a patient cannot access Bicalutamide, therapeutic alternatives within the first-generation NSAA class include:

• Flutamide (Eulexin): 250 mg TID. Higher GI toxicity (diarrhea) and hepatotoxicity risk. Generic available at comparable cost.
• Nilutamide (Nilandron): 300 mg daily × 30 days, then 150 mg daily. Unique adverse effects including visual adaptation delay (13–57% of patients) and interstitial pneumonitis risk. Less commonly stocked.

Second-generation antiandrogens (Enzalutamide, Apalutamide, Darolutamide) are not pharmacological equivalents and have different approved indications, primarily for castration-resistant or high-risk castration-sensitive disease. Switching to these agents solely for access reasons is generally not appropriate unless the clinical indication supports it.

Monitoring Considerations

When prescribing Bicalutamide, standard monitoring includes:

• Liver function tests (LFTs): At baseline, monthly for the first 4 months, then periodically. Bicalutamide is a recognized hepatotoxin (Likelihood Score B per LiverTox).
• PSA monitoring: Per standard prostate cancer treatment protocols
• Signs of antiandrogen withdrawal syndrome: If Bicalutamide is discontinued in castration-resistant disease, PSA decline may occur (withdrawal effect)

Availability Picture

The following summarizes the current Bicalutamide availability landscape:

• FDA shortage status: Not in shortage
• Generic manufacturers: Multiple (≥5 active suppliers)
• Dosage form: 50 mg oral tablets only
• Chain pharmacy availability: Variable — some locations may not stock it routinely
• Independent pharmacy availability: Generally better, as these pharmacies can order from multiple wholesalers
• Specialty pharmacy: Readily available through oncology specialty pharmacies
• Mail-order: Widely available through PBM-affiliated mail-order pharmacies

Cost and Access Data

Cost should not be a significant barrier for most patients on Bicalutamide:

• Generic Bicalutamide (cash with coupon): $20–$24 for 30 tablets (50 mg)
• Generic Bicalutamide (retail, no coupon): ~$267 for 30 tablets
• Brand Casodex (retail): ~$267–$325 for 30 tablets
• Insurance coverage: Tier 1–2 on most formularies. Prior authorization generally not required for the generic.
• Medicare Part D: Covered as a standard generic. Copay typically $0–$15.

For uninsured or underinsured patients, the AZ&Me Prescription Savings Program (AstraZeneca) may provide the medication at no cost. Discount programs such as GoodRx and SingleCare are also effective for reducing the cash price of the generic.

For more cost details, see the patient-facing article on saving money on Casodex, or the provider guide on helping patients save money.

Tools and Resources for Providers

The following resources can help your practice and patients navigate Bicalutamide access:

Medfinder for Providers

Medfinder offers a provider-focused tool that allows clinical staff to search for real-time pharmacy stock of Bicalutamide by ZIP code. This can be integrated into your clinic workflow when patients report difficulty filling prescriptions.

Prescribing Workflow Recommendations

1. E-prescribe to a confirmed pharmacy: Before sending the prescription, verify the pharmacy has Bicalutamide in stock or can order it quickly
2. Include a note for the pharmacist: "Generic Bicalutamide acceptable from any manufacturer" to avoid unnecessary delays
3. Provide patients with backup options: Give patients a printed list of nearby pharmacies or direct them to Medfinder
4. Consider 90-day prescriptions: Reduces refill frequency and allows mail-order fulfillment
5. Proactive refill coordination: Encourage patients to initiate refills 5–7 days before running out

Patient Assistance Resources

• AZ&Me: AstraZeneca's patient assistance program (azandmeapp.com)
• NeedyMeds: needymeds.org — comprehensive PAP database
• RxAssist: rxassist.org — patient assistance program directory
• GoodRx/SingleCare: Free discount coupons reducing generic price to $20–$24/month

Looking Ahead

Bicalutamide's position as the standard first-generation antiandrogen for combined androgen blockade remains stable. The competitive generic market, with multiple active manufacturers, provides supply resilience. While the expanding off-label use of Bicalutamide may continue to increase overall demand, this is unlikely to cause sustained shortages given the multiple-supplier landscape.

Providers should continue monitoring the FDA Drug Shortage Database for any changes and maintain familiarity with therapeutic alternatives in case isolated supply disruptions affect their patient population.

Final Thoughts

Bicalutamide remains readily available, affordable, and well-supported by generic competition. The primary challenge for patients in 2026 is local pharmacy stocking, not supply adequacy. By incorporating stock verification tools like Medfinder into your clinical workflow and proactively counseling patients on refill strategies, you can minimize treatment disruptions and ensure therapy continuity.

For the patient perspective on this topic, see our article on what patients need to know about the Casodex shortage in 2026. For guidance on helping patients locate the medication, read the provider's guide to finding Casodex in stock.